Find Irpagratinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2230974-62-4, Absk011, Absk-011, X46b7jm4a8, N-[(3s,4s)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide, N-((3s,4s)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido(3,4-d)pyrimidin-2-yl)amino)oxan-4-yl)prop-2-enamide
Molecular Formula
C28H32F2N6O5
Molecular Weight
570.6  g/mol
InChI Key
PGRHEHZIRYNZDV-FUHWJXTLSA-N
FDA UNII
X46B7JM4A8

Irpagratinib
Irpagratinib is an orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, irpagratinib is specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to the inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.
1 2D Structure

Irpagratinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(3S,4S)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide
2.1.2 InChI
InChI=1S/C28H32F2N6O5/c1-6-21(37)32-16-7-8-41-12-18(16)34-27-31-11-15-9-17(22-23(29)19(38-3)10-20(39-4)24(22)30)33-26(25(15)35-27)36-13-28(2,14-36)40-5/h6,9-11,16,18H,1,7-8,12-14H2,2-5H3,(H,32,37)(H,31,34,35)/t16-,18+/m0/s1
2.1.3 InChI Key
PGRHEHZIRYNZDV-FUHWJXTLSA-N
2.2 Other Identifiers
2.2.1 UNII
X46B7JM4A8
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 2230974-62-4

2. Absk011

3. Absk-011

4. X46b7jm4a8

5. N-[(3s,4s)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide

6. N-((3s,4s)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido(3,4-d)pyrimidin-2-yl)amino)oxan-4-yl)prop-2-enamide

7. Refchem:1087493

8. Irpagratinib [inn]

9. Orb2277624

10. Chembl5314522

11. Schembl20332300

12. Gtpl12869

13. Ex-a8168

14. Example 790 [us10968220]

15. Da-54384

16. Hy-156618

17. Cs-0886364

18. H42845

19. 2-propenamide, N-[(3s,4s)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methyl-1-azetidinyl)pyrido[3,4-d]pyrimidin-2-yl]amino]tetrahydro-2h-pyran-4-yl]-

20. N-((3s,4s)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl)amino)tetrahydro-2h-pyran-4-yl)acrylamide

21. N-[(3s,4s)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methyl-1-azetidinyl)pyrido[3,4-d]pyrimidin-2-yl]amino]tetrahydro-2h-pyran-4-yl]-2-propenamide

2.4 Create Date
2018-12-15
3 Chemical and Physical Properties
Molecular Weight 570.6 g/mol
Molecular Formula C28H32F2N6O5
XLogP32.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count12
Rotatable Bond Count9
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area120
Heavy Atom Count41
Formal Charge0
Complexity899
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Looking for 2230974-62-4 / Irpagratinib API manufacturers, exporters & distributors?

Irpagratinib manufacturers, exporters & distributors 1

77

PharmaCompass offers a list of Irpagratinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Irpagratinib manufacturer or Irpagratinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Irpagratinib manufacturer or Irpagratinib supplier.

API | Excipient name

Irpagratinib

Synonyms

2230974-62-4, Absk011, Absk-011, X46b7jm4a8, N-[(3s,4s)-3-[[6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-yl]amino]oxan-4-yl]prop-2-enamide, N-((3s,4s)-3-((6-(2,6-difluoro-3,5-dimethoxyphenyl)-8-(3-methoxy-3-methylazetidin-1-yl)pyrido(3,4-d)pyrimidin-2-yl)amino)oxan-4-yl)prop-2-enamide

Cas Number

2230974-62-4

Unique Ingredient Identifier (UNII)

X46B7JM4A8

About Irpagratinib

Irpagratinib is an orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, irpagratinib is specifically and irreversibly binds to the cysteine residue at position 552 (Cys 552) that is within the active site of FGFR4. This blocks FGFR4 autophosphorylation and activation of receptor tyrosine kinase activity that would normally occur after binding to its ligand, fibroblast growth factor 19 (FGF19), which both inhibits FGFR4-mediated signaling and leads to the inhibition of tumor cell proliferation in FGF19- and FGFR4-overexpressing cells. FGFR4, a receptor tyrosine kinase, is involved in angiogenesis and in the proliferation, differentiation, and survival of tumor cells. FGFR4 expression is associated with poor prognosis. FGF19 is overexpressed by certain tumor cell types.

Irpagratinib Manufacturers

A Irpagratinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Irpagratinib, including repackagers and relabelers. The FDA regulates Irpagratinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Irpagratinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Irpagratinib Suppliers

A Irpagratinib supplier is an individual or a company that provides Irpagratinib active pharmaceutical ingredient (API) or Irpagratinib finished formulations upon request. The Irpagratinib suppliers may include Irpagratinib API manufacturers, exporters, distributors and traders.

Irpagratinib GMP

Irpagratinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Irpagratinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Irpagratinib GMP manufacturer or Irpagratinib GMP API supplier for your needs.

Irpagratinib CoA

A Irpagratinib CoA (Certificate of Analysis) is a formal document that attests to Irpagratinib's compliance with Irpagratinib specifications and serves as a tool for batch-level quality control.

Irpagratinib CoA mostly includes findings from lab analyses of a specific batch. For each Irpagratinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Irpagratinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Irpagratinib EP), Irpagratinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Irpagratinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty